Hageal cancer. Anticancer Res 2011;31(2):63338 9. Yamasaki M, Miyata H, Tanaka K, Shiraishi

Hageal cancer. Anticancer Res 2011;31(2):63338 9. Yamasaki M, Miyata H, Tanaka K, Shiraishi O, Motoori M, Peng YF et al. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma on the esophagus. Oncology 2011;80(five):30713 10. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357(17):1705715 11. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357(17): 1695704 12. Tanaka Y, Yoshida K, Sanada Y, Osada S, Yamaguchi K, Takahashi T. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol 2010;66(six):1159165 13. Nakajima M, Kato H. Treatment possibilities for esophageal squamous cell carcinoma. Expert Opin Pharmacother 2013; 14(10):1345354 14. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277(5698):66567 15. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities applying paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003;104(1):12129 16. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15(six):955AcknowledgmentsThe authors declare that they have no conflict of interest.AGO2/Argonaute-2 Protein medchemexpress
Pasco et al. BMC Obesity 2014, 1:9 http://www.biomedcentral.com/2052-9538/1/RESEARCH ARTICLEOpen AccessBody mass index and measures of physique fat for defining obesity and underweight: a cross-sectional, population-based studyJulie A Pasco1,2*, Kara L Holloway1, Amelia G Dobbins1, Mark A Kotowicz1,two, Lana J Williams1 and Sharon L Brennan1,AbstractBackground: The physique mass index (BMI) is usually made use of as a surrogate marker for adiposity.DKK1 Protein Biological Activity Even so, the BMI indicates weight-for-height without having contemplating variations in physique composition and also the contribution of physique fat to all round physique weight.PMID:25818744 The aim of this cross-sectional study was to recognize sex-and-age-specific values for percentage physique fat ( BF), measured making use of entire physique dual energy x-ray absorptiometry (DXA), that correspond to BMI 18.five kg/m2 (threshold for underweight), 25.0 kg/m2 (overweight) and 30.0 kg/m2 (obesity) and examine the prevalence of underweight, overweight and obesity inside the adult white Australian population applying these BMI thresholds and equivalent values for BF. These analyses utilise information from randomly-selected men (n = 1446) and ladies (n = 1045), age 206 years, who had concurrent anthropometry and DXA assessments as a part of the Geelong Osteoporosis Study, 2001008. Benefits: Values for BF cut-points for underweight, overweight and obesity were predicted from sex, age and BMI. Making use of these cut-points, the age-standardised prevalence among guys for underweight was 3.1 (95 CI two.1, 4.1), overweight 40.four (95 CI 37.7, 43.1) and obesity 24.7 (95 CI 22.two, 27.1); amongst women, prevalence for underweight was 3.eight (95 CI 2.6, five.0), overweight 32.3 (95 CI 29.five, 35.2) and obesity 29.five (95 CI 26.7, 32.3). Prevalence estimates utilizing BMI criteria for guys were: underweight 0.6 (95 CI 0.2, 1.1), overweight 45.5 (95 CI 42.7, 48.2) and obesity 19.7 (95 C.